536 related articles for article (PubMed ID: 32243222)
1. Molecular Risk Stratification in Aggressive B-Cell Lymphomas.
Frosch ZAK; Landsburg DJ
J Clin Oncol; 2020 Jun; 38(18):2014-2017. PubMed ID: 32243222
[No Abstract] [Full Text] [Related]
2. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
3. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
5. BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?
Dunleavy K; Davis RE; Landgren O; Staudt LM; Wilson WH
Blood; 2007 Jan; 109(2):843-4; discussion 844-5. PubMed ID: 17210865
[No Abstract] [Full Text] [Related]
6. Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
Kojima M; Amaki J; Ogiya D; Ando K; Nakamura N
J Clin Exp Hematop; 2020 Jun; 60(2):60-61. PubMed ID: 32404573
[No Abstract] [Full Text] [Related]
7. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
8. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
9. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Coiffier B; Salles G
Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
[No Abstract] [Full Text] [Related]
10. CHOP plus rituximab--balancing facts and opinion.
Cheson BD
N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
[No Abstract] [Full Text] [Related]
11. Pediatric B-cell lymphoma, unclassifiable, with intermediate features between those of diffuse large B-cell lymphoma and Burkitt lymphoma: a report of two cases.
Zhang S; Wilson D; Czader M
Ann Lab Med; 2015 Mar; 35(2):254-6. PubMed ID: 25729731
[No Abstract] [Full Text] [Related]
12. Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Landsburg DJ; Koike A; Nasta SD; Svoboda J; Schuster SJ; Wasik MA; Caponetti GC
Cancer Immunol Immunother; 2021 Mar; 70(3):869-874. PubMed ID: 32857184
[TBL] [Abstract][Full Text] [Related]
13. Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.
Bewarder M; Kaddu-Mulindwa D; Kos IA; Lesan V; Held G; Poeschel V; Thurner L; Bittenbring JT; Schmitz N; Truemper L; Pfreundschuh M; Christofyllakis K; Loeffler M; Altmann B; Ziepert M
Haematologica; 2023 Oct; 108(10):2844-2849. PubMed ID: 36815369
[No Abstract] [Full Text] [Related]
14. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
[No Abstract] [Full Text] [Related]
15. [Significance and application of c-myc in diffuse large B-cell lymphoma].
Huang WT; Lü N; Guo L
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):638-40. PubMed ID: 24314257
[No Abstract] [Full Text] [Related]
16. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
17. [B-cell lymphoma with concurrent myc/IgH and bcl-2/IgH translocations: report of a case].
Li L; Liu YH; Zhuang HG; Luo DL; Xu FP; Luo XL; Xu J; Zhang KP
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):50-1. PubMed ID: 21429362
[No Abstract] [Full Text] [Related]
18. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
Mitroviç Z; Aurer I; Radman I; Ajdukoviç R; Sertiç J; Labar B
Haematologica; 2007 Jul; 92(7):998-9. PubMed ID: 17606457
[TBL] [Abstract][Full Text] [Related]
19. Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder.
Nascimento AF; Winters GL; Pinkus GS
Am J Surg Pathol; 2007 Sep; 31(9):1344-50. PubMed ID: 17721189
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax Boosts Benefits of R-EPOCH in Aggressive B-Cell Lymphomas.
Oncologist; 2020 Jul; 25 Suppl 1(Suppl 1):S14-S15. PubMed ID: 32588924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]